Predicted to enable several functions, including DNA-binding transcription factor activity, RNA polymerase II-specific; cholesterol binding activity; and promoter-specific chromatin binding activity. Predicted to be involved in several processes, including cell redox homeostasis; negative regulation of transcription by RNA polymerase II; and regulation of odontoblast differentiation. Predicted to act upstream of or within several processes, including cellular response to cholesterol; neurogenesis; and regulation of organelle organization. Predicted to be located in cytosol; endoplasmic reticulum membrane; and nucleoplasm. Predicted to be part of protein-containing complex. Predicted to be active in nucleus. Orthologous to human NFE2L1 (NFE2 like bZIP transcription factor 1); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 4,4'-sulfonyldiphenol; 4-hydroxynon-2-enal.
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NFE2L1 mRNA
4-hydroxy-2-nonenal promotes the reaction [NFE2L1 protein binds to GGT1 promoter] and 4-hydroxy-2-nonenal results in increased expression of and results in increased localization of NFE2L1 protein
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein] and Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein]
[NFE2L1 protein alternative form co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of NFE2L2 mRNA more ...
[NFE2L1 protein alternative form co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of NFE2L2 mRNA more ...
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NFE2L1 mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein] and Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein]
[Flame Retardants co-treated with pentabromodiphenyl ether co-treated with decabromobiphenyl ether co-treated with hexabromocyclododecane] results in increased expression of NFE2L1 mRNA
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NFE2L1 mRNA
PPARGC1A affects the reaction [Doxorubicin results in decreased expression of NFE2L1 protein] and PPARGC1A affects the reaction [Doxorubicin results in increased expression of NFE2L1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Glucose results in increased expression of NFE2L1 protein] and Glucose promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol A] results in increased expression of NFE2L1 mRNA
[ascorbate-2-phosphate co-treated with GULO protein] affects the expression of and affects the localization of NFE2L1 protein and NFE2L1 protein affects the reaction [ascorbate-2-phosphate results in increased expression of SP7 mRNA]
[NFE2L1 protein alternative form co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of NFE2L2 mRNA more ...